PO-0070  **PECULIARITIES OF THE GROWTH HORMONE AND INSULIN-LIKE GROWTH FACTOR (IGF-1, IGFBP-3) SECRETION IN GENETICALLY DETERMINED TYPES OF SHORT STATURE IN UZBEKISTAN**

NSI Ibragimova, MD Mirkhaydarova. Laboratory of Genomics, Institute of Bioorganic Chemistry Academy of Sciences Republic of Uzbekistan, Tashkent, Uzbekistan

10.1136/archdischild-2014-307384.741

**Goal** To study the growth hormone (GH) and insulin-like growth factor (IGF-1, IGFBP-3) secretion in genetically determined types of short stature (GDSS) in Uzbekistan.

**Materials and methods** We examined 92 patients with GDSS (11 - Russel-Silver syndrome (RSS), 16 - Noonan syndrome (NS), 10 - Sekkel syndrome (SS), 9 - Prader-Willi syndrome (PWS), 8 - Cornelius de Lange syndrome (CLS), 38 girls with TS) at the age of 7–18. A level of GH, IGF-1, IGFBP-3, anthropometry (SDS) was studied.

**Results** Stunting of various degrees of expression was observed in all patients with GDSS but it was more expressed in patients with RSS (-5.16 ± 1.18 SDS), SS (-4.18 ± 1.12 SDS) and CLS (-6.10 ± 1.14 SDS). A reliably low level of GH vs. the control was found in patients with CLS (0.64 ± 0.05 ng/ml, p < 0.05), RSS (0.7 ± 0.04 ng/ml, p < 0.05), SS (1.02 ± 0.07 ng/ml, p < 0.05) on the background of a low level of IGF-1 and IGFBP-3.

**Conclusions** Patients with NS, TS and PWS had a level of GH within the lower limit normal, 12 girls with TS had a GH level which was reliably low (0.04 ± 0.05 ng/ml, p < 0.05) but IGF-1 and IGFBP-3 rates corresponded to the lower limit of the age norm.

PO-0072  **A BOY WITH DECELERATED LINEAR GROWTH WITH NORMAL GROWTH HORMONE (GH) – INSULIN-LIKE GROWTH FACTOR-1 (IGF-I) AXIS HAD AN EXCEPTIONAL RESPONSE TO GH THERAPY**

A Soliman, F Alyafei, AML Sabt, A Adel. Pediatrics, Hamad Medical Centre, Doha, Qatar

10.1136/archdischild-2014-307384.743

Y M is a boy who presented at the age of 5.5 years with slow growth He had a birth weight = 3.1 kg and length = 49.5 cm. Infantile and early neonatal periods are uneventful. He had normal development and appropriate nutritional history. No family history of endocrinopathy and/ or short stature was reported. His measurements were: weight = 16.9 kg, Height = 104 cm (HtSDS = -1.8), growth velocity (GV = 1 cm/y) and BMI = 16 and mid-parental height (MPHt) SDS = -0.6. He had no rickets is a disease in on growing bones due to precipitate disorders of calcium (Ca) and phosphor (P) in matrix of growth plate before epiphysial closing. Different types for rashes including nutritional, hypophosphatemic and vitamin-D dependent rickets (VDDR). VDDR is a result of severe vitamin D deficiency that had tow subtype:

A) type -1(VDDR-1) because of defect of 1-alfa-hydroxilase enzyme.

B) type -2(VDDR-2) because of mutation in intracellular vitamin-D receptor (VDR) associated with some especial symptoms like alopecia (global head hair loss) and short stature. this disease needs to high dose of vitamin-D analogues also calcium supplement. although response to treatment is variable.

**Cases Introduction** We introduce 3 cases of VDDR-2 in a family (2 sisters aged 1.5, 5 years and their 5 years old cousin) who referred to endocrine and metabolic centre in Emam-Reza hospital in Mashhad presenting limb deformities, wide wrist, seizure, disorder in dental growth, alopecia, several bone fractures. they had not been recovered despite receiving sufficient treatment. it was notable when they received growth hormone therapy because of growth failure, their rickets improved dramatically by clinical, laboratory, radiological.

**Discussion** According to discover several clinical indication for growth hormone therapy during last 50 years, still there are not enough studies about growth hormone therapy in VDDR. As second type of vitamin-D dependent rickets sometimes needs to long time calcium infusion or high dosage of active vitamin-D analogues, so it seems that growth hormone therapy in these patients especially with short stature may improve linear growth and rickets symptoms too.

**Abstract PO-0072 Table 1** Growth data of the patient before and after GH therapy

<table>
<thead>
<tr>
<th>Age /year</th>
<th>BMI</th>
<th>HSDS</th>
<th>IGF1 ng/ml</th>
<th>Bone age</th>
<th>Notes</th>
<th>Tanner stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.48</td>
<td>16</td>
<td>-0.45</td>
<td>65</td>
<td>ND</td>
<td>Started GH</td>
<td></td>
</tr>
<tr>
<td>5.5</td>
<td>16</td>
<td>-1.84</td>
<td>70</td>
<td>3</td>
<td>Tanner 1</td>
<td></td>
</tr>
<tr>
<td>5.7</td>
<td>16</td>
<td>-0.7</td>
<td>92</td>
<td>4</td>
<td>Tanner 2</td>
<td></td>
</tr>
<tr>
<td>6.4</td>
<td>16</td>
<td>-0.32</td>
<td>148</td>
<td>4</td>
<td>Tanner 3</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>15</td>
<td>-0.28</td>
<td>279</td>
<td>5</td>
<td>Tanner 4</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>17</td>
<td>0.15</td>
<td>295</td>
<td>6</td>
<td>Tanner 5</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>18</td>
<td>0.5</td>
<td>195</td>
<td>8.5</td>
<td>Tanner 6</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>20</td>
<td>0.5</td>
<td>325</td>
<td></td>
<td>Tanner 7</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>22</td>
<td>0.5</td>
<td>447</td>
<td></td>
<td>Tanner 8</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>22</td>
<td>0.83</td>
<td>514</td>
<td></td>
<td>Tanner 9</td>
<td></td>
</tr>
</tbody>
</table>

10.1136/archdischild-2014-307384.742
dysmorphic features, skeletal anomalies, goitre or pigmentation. The rest of the examination was unrevealing.

Investigations showed normal CBC, ESR, and liver and renal and thyroid functions. Sweat chloride test, and tissue trans-glutaminase concentrations were normal. His IGF-I level = 70 (IGF-I SDS = -1) and his bone age = 3 years. The peak GH response to clonidine stimulation test = 10 ng/dL. Brain MRI showed normal pituitary gland.

Because of the decelerated growth and marginally low IGF-I a trial of GH therapy was started (0.035 mg/kg/day s.c. HS). A rapid catch-up of growth occurred during the first 3 years of treatment that was maintained at a slower pace during the following 5 years. Testicular enlargement started at 11 years and at 12 years his HtSDS = 0.8 and bone age = 12.5 years. His predicted adult height = 181 cm.

Conclusion Prolonged GH treatment of this boy (normal GH–IGF-I axis) with GH unexpectedly resulted in a HTSDS which surpassed his MPhtSDS by 1.4 SD.

---

**PO-0074**  | **PESSO-A-BARTTER’S SYNDROM AS A FIRST MANIFESTATION OF CYSTIC FIBROSIS IN INFANCY**

5 Furtik, T Jakovska, L Spirevska. Center for Cystic Fibrosis, University Children’s Hospital, Skopje, Macedonia

10.1136/archdischild-2014-307384.744

**Background and aims** Metabolic alkalosis in association with low serum electrolyte concentration (hyponatremia, hypochloremia, and hypokalemia) is known complication of cystic fibrosis (CF) in infancy. The condition is a metabolic mimickery of Bartter’s syndrome, therefore is sometimes referred to as pseudo-Bartter’s syndrome in CF. The aims of study were to estimate the prevalence of this metabolic disorder as a first manifestation of CF and the influence of some clinical and genetic factors on its developing.

**Methods** The records of all 85 newly diagnosed infants with CF in the period from 1998 to 2013 were reviewed. In addition to data of acid-base and electrolyte status at first admission, clinical and CFTR genotype data of patients with pseudo-Bartter’s syndrome were analysed.

**Results** 16 infants had manifestations of hyponatremic/hyochloremic dehydration with metabolic alkalosis, therefore the prevalence of pseudo-Bartter’s syndrome among newly diagnosed infants with CF in our region was 18.8%. Mean age of patients was 3.5 (range 1–8) months. Most of them were breastfed. Mean values of blood pH, serum bicarbonate, sodium, chloride and potassium (mmol/L) were: 7.57 ± 0.06, 44.89 ± 10.1136; 10.1136/archdischild-2014-307384.745

**PO-0075**  | **HEAD CIRCUMFERENCE IN THE FIRST YEAR AFTER BIRTH – THE EFFECT OF PRENATAL EXPOSURE TO ORGANOCHLORINES AND PHThALATES**

M de Cock, 1M de Boer, 2M Lamoree, 3T Legler, 4M van de Boer. 1Health and Life Sciences, VU University, Amsterdam, Netherlands; 2Health Sciences, VU University, Amsterdam, Netherlands; 3Institute for Environmental Studies, VU University, Amsterdam, Netherlands

10.1136/archdischild-2014-307384.745

**Background** Children with autism may experience increased head growth during the first year of life. Furthermore, early life exposure to endocrine disrupting chemicals (EDCs) may be associated with an increased risk of autism. Exposure to EDCs has been associated with fetal head circumference (HC), however research on long-term effects is scarce.

**Objective** To assess the association between prenatal exposure to various EDCs and HC in the first year of life.

**Methods** Cord plasma or breast milk was used to determine exposure to amongst others dichlorodiphenylchloroethenylene (DDE), mono (2-ethyl-5-hydroxyhexyl)phthalate (MEHHP), and mono (2-ethyl-5-carboxypentylo)phthalate (MECPP). Data on HC until 11 months after birth was obtained. Mixed models were composed for each compound. Exposure quartiles, time, and gender were added to the models as fixed effects. Subject was added as a random effect.

**Results** Boys with high MECPP exposure had a consistently higher HC than lower exposed boys (p = 0.047). This was also observed for girls in Q2 for both MEHHP (p = 0.018) and DDE (p < 0.001) exposure. For MEHHP the difference with the quartile showing the smallest HC was 2 cm at 11 months of age, which was not statistically significant (HC Q2: 44.9, 95% CI 43.2–46.7; HC Q3: 42.9, 95% CI 42.2–43.5).

**Conclusion** For MECPP, MEHHP, and DDE exposure over time, a higher HC was observed in low exposed children in a gender-specific way. Follow-up is warranted to see if associations persist into later childhood and are related to autism spectrum disorders.

---

**PO-0076**  | **PREVALENCE OF OVERWEIGHT AND OBESITY AMONG 5–6-YEAR-OLD CHILDREN IN NORTH PART OF SERBIA**

5 Turndic, Department of Pediatrics, Local Health Center “Dr Milorad Mika Pavlovic”, Indjija, Serbia

10.1136/archdischild-2014-307384.746

**Background and aims** Overweight and obesity among children became an important public health concern as their prevalence within the preschool population has been markedly increased in last decades. The aim of the present study was to examine and compare the prevalence of overweight and obesity among 5–6 year old children either sex in year 2003 and year 2013.

**Methods** Overweight and obesity were measured by body mass index (BMI). BMI 85–95th percentile was considered as overweight and BMI ≥ 95th percentile represents obesity. The study was performed in the total population of 859 nonselected 5–6 year old children (423 in 2003 and 436 in 2013) by retrospective analysis of their medical documentations.

**Results** The overall prevalence of overweight in 2003 was 9.63%, whereas the prevalence of obesity was 9.46%. However, 10 years later, in 2013, the prevalence of overweight was significantly higher (15.6%) as well as the prevalence of obesity (13.3%). Prevalence of overweight and obesity among...